You are here
BASF Files Lawsuit Over Patent Infringement
BASF filed a lawsuit against Willowood LLC to halt the ongoing infringement of certain BASF patents relating to the manufacture and use of its fungicide pyraclostrobin.
BASF has led the way in the research and development (R&D) of active ingredients like pyraclostrobin that control fungal diseases and offer plant health benefits. BASF is committed to investing in the research and development of new and innovative products and protecting the intellectual property, which results from this development, according to a BASF statement. Each new active ingredient represents an investment of more than $250 million in the agricultural industry.
“Farmers rely on innovation from partners like BASF to help improve the yield and quality of their crop,” says Paul Rea, senior vice president, BASF North America. “BASF remains at the forefront of crop protection product development and innovation, bringing new solutions to growers.”
BASF has a portfolio of patents surrounding pyraclostrobin-containing products, mixtures, and intermediates in the U.S. and globally. Pyraclostrobin is the key ingredient in BASF plant health fungicides, and is approved by the U.S. EPA for controlling a broad range of diseases and improving plant health, which can result in improvements in crop growth and quality.
These products include Headline SC, Headline, Headline AMP, Priaxor, Pristine, Merivon, Twinline, Nexicor, Cabrio, Insignia, and Xanthion fungicides, Stamina F3 and Stamina F4 cereals fungicide seed treatments.
“Growers using BASF fungicides can be confident that the products are manufactured to the highest quality standards and will continue to perform reliably,” says Rea. “We expect continued growth for our pyraclostrobin-based products and mixtures, as they have proven to be highly effective and reliable fungicides due to proprietary, high-quality R&D and formulation expertise.”
To continue the significant investments in the research and development of new compounds, BASF will protect the investments already made through its legally enforceable intellectual property rights, according to the company statement.